3DM Inc. Secures $1.7 Million Financing For Clinical Development of PuraMatrix Hydrogels

Boston, Mass. — October28, 2004 3DM, Inc., a Cambridge-based developer of synthetic biomaterials, has raised $1.7 million in a first round of venture capital from Technology Directors, Inc., and other investors. The funding will accelerate 3DM's clinical development of its lead product, PuraMatrix™ synthetic peptide hydrogels for use in orthopedic applications ranging from bone fill, to spinal fusion, to implant coatings, to drug delivery. The Company has successfully completed pre-clinical safety and efficacy testing of PuraMatrix in animal studies and plans to submit its bone fill indication to the FDA early in 2005. Human clinical trials for other orthopedic applications will occur later in 2005.

The funding comes on the heels of a successful product launch with BD Biosciences, establishing 3DM's PuraMatrix line as an enabling nanotechnology biomaterial for next generation cell culture and in vivo research and bioproduction. Concurrent with the launch, R&D Magazine recently awarded PuraMatrix its 42nd annual R&D 100 Prize as one of the most significant new products to impact life science and medical research, a prestigious award held by the likes of Taxol and the nicotine patch.

"In the last 12 months, 3DM management and its world-class scientific founding team have established PuraMatrix as one of the best-selling synthetic scaffolds for in vitro and in vivo drug discovery research world wide." stated John Maki, Managing Director of Technology Directors Inc. "The combination of BD Bioscience partnership, multiple industry collaborations and 3DM's own aggressive clinical development program promises to establish PuraMatrix as the next standard in biocompatible scaffolds for medical device and drug delivery applications."

The funding adds two experienced venture investors to 3DM's Board of Directors. John Maki, Managing Director of Technology Directors, Inc. and previously an investor with Audax Group and Bain Capital, was founding investor or lead in the re-capitalizations of over 15 companies, including Physio Control, Wesley Jessen Visioncare, Large Scale Biology, and DeNovis, among other companies. Adam Kirsch was a founder and remains a Special Limited Partner of Bain Capital, where he served on the boards of numerous private and public companies including Dade Diagnostics, Blue Ridge Pharmaceuticals, and Nutraceutical International.

"In addition to adding two terrific venture investors to our Board, this funding will accelerate clinical development of PuraMatrix gels as a component of next generation medical implants, enhancing healthy tissue ingrowth and regeneration," said Zen Chu, 3DM's President and co-founder. "In addition to orthopedic device applications, PuraMatrix enhances performance of devices for cardiac, neurological, wound healing and drug delivery applications. 3DM is collaborating with premier medical device companies to demonstrate PuraMatrix's utility across each of these areas."

About PuraMatrix™

PuraMatrix Hydrogels are used to create synthetic nanofiber scaffolds to culture cells for basic research, drug discovery and bioproduction. Clinical versions of PuraMatrix are currently in animal testing for medical device applications in orthopedic implants and cardiac regeneration.

PuraMatrix holds many advantages over current solutions:
* Synthetic and transparent yet biocompatible hydrogel composition composed of 99% water
* Cultures and supports attachment of a wide variety of cell & tissue types
* Supports hepatotoxicity, angiogenesis, cell migration, neural outgrowth assays
* Promotes differentiation of hepatocyte progenitor cells and other cell types
* Devoid of animal-derived components and pathogens
* Other potential applications include stem cell proliferation, tumor cell motility, angiogenesis assays, in vivo analyses of tissue regeneration
* Easily mixed with cells and/or bioactive molecules for creating highly defined culture environments

BD™ PuraMatrix™ is distributed exclusively through BD Biosciences. Product information can be found at http://www.bdbiosciences.com/discovery_labware/Products/tissue_engineering/PuraMatrix/ or by calling BD Biosciences at 1-800-343-2035.

PuraMatrix™ is forward compatible with in vivo implant studies and bioproduction requirements, and is already in use at major pharmaceutical companies and clinical research institutions. Other versions of PuraMatrix are compatible with cGMP quality requirements and clinical therapeutics and are available directly from 3DM Inc.

About 3DM Inc.

3DM is a privately-held specialty biomaterials and medical device company headquartered in Cambridge, Massachusetts. The patented technology, exclusively licensed from Massachusetts Institute of Technology, was pioneered through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert Langer, Alexander Rich, Carlos Semino and Lisa Spirio. Contact 3DM directly for supplying high volume and GMP-quality applications for bioproduction, medical devices and drug delivery applications.

Source:                  3DM Inc.

Contact:                 Zen Chu, President
                                contact@puramatrix.com 877-430-9595

Website:                www.PuraMatrix.com